Generics in cardiovascular diseases market to 2018 - Loss of Lipitor Market Exclusivities

455 views

Published on

Market characterization of the generics in cardiovascular disorders market, including market size, annual cost of treatment and treatment usage pattern.

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
455
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Generics in cardiovascular diseases market to 2018 - Loss of Lipitor Market Exclusivities

  1. 1. Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor MarketExclusivities and Impending Patent Expirations of Plavix to Drive GenericSubstitutionThe report provides in-depth analysis of drivers and barriers that impact the globalcardiovascular disorders market. The report analyzes the generics market for cardiovasculardisorders in the US, the top five countries in Europe (the UK, Germany, France, Italy andSpain) and Japan. Treatment usage patterns are forecast until 2018 for the key geographiesas well as the leading therapeutic segments. Furthermore, the report provides competitivebenchmarking for the leading companies and analyzes the mergers, acquisitions andlicensing agreements that shape the global markets. This report is built using data andinformation sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The global generics marketcardiovascular drugs is expected to grow rapidly due to the growing dyslipdemia,thrombosis and hypertension populations in the developed countries, as well as patentexpiries of major blockbusters such as Lipitor (atorvastatin), Plavix (clopidigrel) and Diovan(valsartan). The patent expiries of these blockbuster drugs will trigger generic competitionin the cardiovascular therapeutics market, making it more competitive. In 2010, thegenerics market for cardiovascular drugs was estimated at $20.5 billion, indicating a yearon year decline of 0.9% from 2004-2010. Patent expiries of the leadingantiplatelets/antithrombotics such as Plavix (clopidigrel) and Lovenox (enoxaparin) and lipidlowering blockbuster Lipitor in 2010-2012, resulting in uptake of generics, is expected tocause the market to increase significantly from 2010 to 2018.Buy your copy of this report @ http://www.reportsnreports.com/reports/160378-generics-in-cardiovascular-diseases-market-to-2018-loss-of-lipitor-market-exclusivities-and-impending-patent-expirations-of-plavix-to-drive-generic-substitution.htmlScopeAnnualized market data for the generics in cardiovascular disorders market from 2004 to2010, forecast forward to 2018.Analysis of the leading therapeutic segments, including pulmonary arterial hypertension,thrombosis, dyslipidemia, hypertension, coronary artery disease, and Angina Pectoris.Analysis of the generics in cardiovascular disorders market in the leading geographies of theworld, which include the US, the UK, Germany, France, Italy, Spain and Japan.Market characterization of the generics in cardiovascular disorders market, including marketsize, annual cost of treatment and treatment usage pattern.Key drivers and barriers that have a significant impact on the generics market.Coverage of pipeline molecules in various phases of drug development.Competitive benchmarking of leading generic companies. The key companies studied in thisreport areKey M&A activities, licensing agreements that have taken place from 2004 to 2011 in theglobal cardiovascular disorders market.
  2. 2. Major points covered in Table of Contents of this report include:1 Table of Contents2 Generics in Cardiovascular Diseases Market to 2018 – Executive Summary3 Generics in Cardiovascular Diseases Market to 2018 – Introduction4 Generics in Cardiovascular Diseases Market to 2018 – Global Market Overview5 Generics in Cardiovascular Disease Market to 2018 - Geographical Landscape6 Generics in Cardiovascular Diseases Market to 2018: Therapeutic Landscape7 Generics in Cardiovascular Diseases Market to 2018 – Product Pipeline Analysis8 Generics in Cardiovascular Diseases Market to 2018 – Most Promising Pipeline Molecules9 Generics in Cardiovascular Diseases Market to 2018 – Competitive Landscape10 Generics in Cardiovascular Diseases Market to 2018 – Strategic Consolidations11 Generics in Cardiovascular Diseases Market to 2018 – AppendixList of TablesList of FiguresBrowse reports related to Pharmaceuticals @http://www.reportsnreports.com/market-research/pharmaceuticals/Report Details:Published: May 2012No. of Pages: 129Price: Single User License – US$3500 Corporate User License – US$10500
  3. 3. Contact:Priyank TiwariTX, Dallas North - Dominion Plaza,17304, Preston Road,Suite 800, Dallas 75252Tel: +1-888-391-5441sales@reportsandreports.comConnect With Us:

×